Bedaquiline Fumarate丨CAS 845533-86-0

Bedaquiline Fumarate丨CAS 845533-86-0
Product Introduction:
Catalog No.: SS129494
CAS No.: 845533-86-0
Purity: 99.5% min
Product Name: Bedaquiline Fumarate
Molecular Formula: C36H35BrN2O6
Molecular Weight: 671.6
Send Inquiry
Technical Parameters
Description

Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of bedaquiline fumarate丨cas 845533-86-0 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.

 

Specifications of Bedaquiline Fumarate丨CAS 845533-86-0

 

Appearance

White to off-white solid

Identification

The retention time of the major peak in the chromatogram of Assay preparation corresponds to that of the standard preparation as obtained in the assay

Purity

99.5% min

Single impurity

0.1% max

Total impurity

0.5% max

Loss on drying

1.0% max

Residue on ignition

1.0% max

 

 

 

Applications

Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)

Bedaquiline Fumarate丨CAS 845533-86-0 is specifically developed for the treatment of pulmonary MDR-TB in adults and adolescents.

It is used in combination with other anti-TB drugs as part of a comprehensive regimen.

Approved by regulatory bodies such as the U.S. FDA, WHO, and EMA for limited use under specific clinical conditions.

Compassionate Use in Drug-Resistant Infections

Sometimes utilized in extensively drug-resistant tuberculosis (XDR-TB) under emergency or compassionate programs.

Being explored in clinical trials for other mycobacterial infections such as non-tuberculous mycobacteria (NTM).


 

Benefits

Novel Mechanism of Action
Bedaquiline targets mycobacterial ATP synthase, a unique mechanism that inhibits energy production in Mycobacterium tuberculosis, including resistant strains.

Effective Against Resistant Strains
One of the few available drugs with strong efficacy against MDR- and XDR-TB, offering hope for otherwise untreatable cases.

Improved Treatment Outcomes
Clinical studies have shown faster sputum culture conversion, reduced disease transmission, and improved long-term survival when used appropriately.

Oral Administration
Convenient oral dosing (usually 400 mg/day initially) enhances patient compliance compared to injectable regimens.

Global Health Impact
Endorsed by global health initiatives as a breakthrough drug in the fight against drug-resistant TB, especially in high-burden countries.


 

Conclusion

Bedaquiline Fumarate丨CAS 845533-86-0 represents a significant advancement in the treatment of multidrug-resistant tuberculosis. With its novel action and proven clinical effectiveness, it plays a critical role in modern TB management protocols. Continued access and careful stewardship are essential to preserving its efficacy for future generations.

 

Send Inquiry
Beyond Your Expectation
From Science to Life with LEAPChem
contact us